Molecular mechanism of vitamin D receptor action
暂无分享,去创建一个
[1] K. Ozono,et al. The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. , 1990, The Journal of biological chemistry.
[2] D. Edwards,et al. The Steroid Receptor Coactivator-1 Contains Multiple Receptor Interacting and Activation Domains That Cooperatively Enhance the Activation Function 1 (AF1) and AF2 Domains of Steroid Receptors* , 1998, The Journal of Biological Chemistry.
[3] M. Bissonnette,et al. 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a Noncalcemic Analogue of 1α,25-Dihydroxyvitamin D3, Inhibits Azoxymethane-induced Colonic Tumorigenesis , 1995 .
[4] Jeffrey W. Clark,et al. 1α,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1α,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[5] S. Fawell,et al. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. , 1993, Molecular endocrinology.
[6] J. Eisman,et al. Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer , 1996, Journal of cellular biochemistry.
[7] H. DeLuca,et al. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. , 1992, The Journal of biological chemistry.
[8] J. Jones,et al. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. , 1996, Cancer research.
[9] C. Carlberg,et al. Two nuclear signalling pathways for vitamin D , 1993, Nature.
[10] H. DeLuca,et al. Vitamin D deficiency suppresses cell-mediated immunity in vivo. , 1993, Archives of biochemistry and biophysics.
[11] Daniel Metzger,et al. Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.
[12] M. Haussler,et al. Association of 1,25-dihydroxyvitamin D3 with cultured 3T6 mouse fibroblasts. Cellular uptake and receptor-mediated migration to the nucleus. , 1983, The Journal of biological chemistry.
[13] T. Kuroki,et al. Regulation of Terminal Differentiation of Cultured Mouse Epidermal Cells by lα,25-Dihydroxyvitamin D3 , 1983 .
[14] R. Kumar,et al. Metabolism of 1,25-dihydroxyvitamin D3. , 1984, Physiological reviews.
[15] P. Kushner,et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.
[16] W. Pike,et al. Tissue specificity and mechanism of vitamin D receptor up‐regulation during dietary phosphorus restriction in the rat , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] C. Glass,et al. Differential orientations of the DNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. , 1993, Genes & development.
[18] M. Becich,et al. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. , 1995, Urology.
[19] S. de Vos,et al. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines , 1997, The Prostate.
[20] Kevin Struhl,et al. The TAFs in the HAT , 1998, Cell.
[21] L. Dorssers,et al. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. , 1994, Cancer research.
[22] B. Lewis. A Historical Overview , 1996 .
[23] M. Owen,et al. Mutations Involving the Transcription Factor CBFA1 Cause Cleidocranial Dysplasia , 1997, Cell.
[24] H. DeLuca,et al. 1α,25-dihydroxyvitamin D3 a nd 19-nor-1α,25-dihydroxyvitamin 32 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo , 1993 .
[25] V. Chatterjee,et al. Functional analysis of a transactivation domain in the thyroid hormone beta receptor. , 1994, The Journal of biological chemistry.
[26] P. Lomedico,et al. Vitamin D3-retinoid X receptor dimerization, DNA binding, and transactivation are differentially affected by analogs of 1,25-dihydroxyvitamin D3. , 1995, Molecular endocrinology.
[27] Z. Su,et al. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. , 1994, Oncogene.
[28] P. Brachet,et al. 1,25 Dihydroxyvitamin D3 Exerts Regional Effects in the Central Nervous System during Experimental Allergic Encephalomyelitis , 1996, Journal of neuropathology and experimental neurology.
[29] B. Howard,et al. The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.
[30] E. Ritz,et al. Synergistic effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on proliferation and vitamin D receptor expression of rat growth cartilage cells. , 1994, Endocrinology.
[31] R. Uppaluri,et al. Genetic dissection of thyroid hormone receptor beta: identification of mutations that separate hormone binding and transcriptional activation , 1995, Molecular and cellular biology.
[32] M. Stallcup,et al. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[33] H. Koeffler,et al. Structure-function studies on analogues of 1 alpha,25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. , 1990, Cancer research.
[34] R. Evans,et al. The steroid and thyroid hormone receptor superfamily. , 1988, Science.
[35] J. Pike,et al. Human vitamin D receptor-dependent transactivation in Saccharomyces cerevisiae requires retinoid X receptor. , 1996, Molecular endocrinology.
[36] H. Freund,et al. Historical overview. , 2021, Advances in neurology.
[37] P. Chambon,et al. TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.
[38] B. O’Malley,et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. , 1988, Science.
[39] Tatsuya Yoshizawa,et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning , 1997, Nature Genetics.
[40] M. Grunstein. Histone acetylation in chromatin structure and transcription , 1997, Nature.
[41] G. Chiocchia,et al. Combination of cyclosporine A and calcitriol in the treatment of adjuvant arthritis. , 1992, The Journal of rheumatology.
[42] A. Norman,et al. Profile of ligand specificity of the vitamin D binding protein for 1α,25‐dihydroxyvitamin d3 and its analogs , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[43] A. Berdal,et al. Immunolocalization of Vitamin D Receptor and Calbindin-D28k in Human Tooth Germ , 1996, Pediatric Research.
[44] X. Jacq,et al. Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor , 1994, Cell.
[45] F. Deschner,et al. Relationship Between Disease Activity and Serum Levels of Vitamin D Metabolites and PTH in Rheumatoid Arthritis , 1998, Calcified Tissue International.
[46] P. Chambon,et al. Activation function 2 (AF‐2) of retinoic acid receptor and 9‐cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF‐2 activity. , 1994, The EMBO journal.
[47] Thorsten Heinzel,et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.
[48] Thorsten Heinzel,et al. A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.
[49] Andrew J. Bannister,et al. The TAFII250 Subunit of TFIID Has Histone Acetyltransferase Activity , 1996, Cell.
[50] O. Clausen,et al. 1,25‐dihydroxyvitamin D3 and the vitamin D analogue KH1060 induce hyperproliferation in normal mouse epidermis , 1993, Experimental dermatology.
[51] Makoto Sato,et al. Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.
[52] H. DeLuca,et al. Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[53] M. Haussler,et al. Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[54] G. Cooper,et al. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta‐analysis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[55] M. Galligan,et al. Examination of the Potential Functional Role of Conserved Cysteine Residues in the Hormone Binding Domain of the Human 1,25-Dihydroxyvitamin D Receptor (*) , 1996, The Journal of Biological Chemistry.
[56] Thomas Shenk,et al. TATA-binding protein-independent initiation: YY1, TFIIB, and RNA polymerase II direct basal transcription on supercoiled template DNA , 1994, Cell.
[57] Philippe Kastner,et al. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently , 1992, Cell.
[58] J. Eisman,et al. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. , 1983, Cancer research.
[59] A. Norman,et al. Metabolism of the cell differentiating agent 1α,25(OH)2-16-ene-23-yne vitamin D3 by leukemic cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[60] J. Shine,et al. 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. , 1989, Science.
[61] K. Umesono,et al. The nuclear receptor superfamily: The second decade , 1995, Cell.
[62] A. Mackay,et al. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. , 1995, Journal of molecular endocrinology.
[63] B. Katzenellenbogen,et al. Powerful dominant negative mutants of the human estrogen receptor. , 1993, The Journal of biological chemistry.
[64] K. Kristjánsson,et al. Two mutations causing vitamin D resistant rickets: modelling on the basis of steroid hormone receptor DNA‐binding domain crystal structures , 1994, Clinical endocrinology.
[65] Henderson Nk,et al. Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone , 1996, Current opinion in rheumatology.
[66] H. DeLuca,et al. Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. , 1995, Biochimica et biophysica acta.
[67] P. Goldberg. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. (A viewpoint). Part 1. Sunlight, dietary factors and epidemiology. , 1974 .
[68] A. Norman,et al. 1 alpha,25(OH)2 vitamin D3-regulated expression of the eukaryotic genome. , 1994, Nutrition reviews.
[69] S. Cramer,et al. Regulation of 1,25-dihydroxyvitamin D3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. , 1995, Endocrinology.
[70] S. Minucci,et al. The histone acetylase PCAF is a nuclear receptor coactivator. , 1998, Genes & development.
[71] D. Peehl,et al. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.
[72] R. Gniadecki,et al. Stimulation of epidermal proliferation in mice with 1 alpha, 25-dihydroxyvitamin D3 and receptor-active 20-EPI analogues of 1 alpha, 25-dihydroxyvitamin D3. , 1995, Biochemical pharmacology.
[73] B. O’Malley,et al. Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). , 1992, The Journal of biological chemistry.
[74] M. Sporn,et al. 1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. , 1994, Cancer research.
[75] Jun Qin,et al. Histone-like TAFs within the PCAF Histone Acetylase Complex , 1998, Cell.
[76] M. Bissonnette,et al. 1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 alpha,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis. , 1995, Cancer research.
[77] J. Eisman,et al. Human and murine osteocalcin gene expression: conserved tissue restricted expression and divergent responses to 1,25-dihydroxyvitamin D3 in vivo. , 1997, Molecular endocrinology.
[78] D. Feldman,et al. The role of vitamin D3 in immunosuppression: lessons from autoimmunity and transplantation. , 1997 .
[79] M. Haussler,et al. Chromosomal Receptor for A Vitamin D Metabolite , 1969 .
[80] R. Gniadecki,et al. Stimulation of epidermal proliferation in mice with 1α,25-dihydroxyvitamin D3 and receptor-active 20-epi analogues of 1α,25-dihydroxyvitamin D3 , 1995 .
[81] R. Kremer,et al. In Vitro Metabolism of the Vitamin D Analog, 22-Oxacalcitriol, Using Cultured Osteosarcoma, Hepatoma, and Keratinocyte Cell Lines (*) , 1996, The Journal of Biological Chemistry.
[82] M. Haussler,et al. Transcription factor TFIIB and the vitamin D receptor cooperatively activate ligand-dependent transcription. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[83] A. Mackay,et al. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[84] G. Whitfield. "A highly conserved region in the hormone-binding domain of the human vitamin D receptor contains residues vital for heterodimerization with retinoid X receptor and for transcriptional activation". , 1995, Molecular endocrinology.
[85] B. O’Malley,et al. Mutant vitamin D receptors which confer hereditary resistance to 1,25-dihydroxyvitamin D3 in humans are transcriptionally inactive in vitro. , 1989, The Journal of biological chemistry.
[86] L. Binderup,et al. 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. , 1991, Biochemical pharmacology.
[87] S. Collins,et al. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. , 1987, Blood.
[88] R. Bouillon,et al. Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.
[89] H. DeLuca,et al. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[90] H. DeLuca,et al. Two Vitamin D Response Elements Function in the Rat 1,25-Dihydroxyvitamin D 24-Hydroxylase Promoter (*) , 1995, The Journal of Biological Chemistry.
[91] J. Eisman,et al. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[92] Y. Liu,et al. Vitamin D Receptors Repress Basal Transcription and Exert Dominant Negative Activity on Triiodothyronine-mediated Transcriptional Activity (*) , 1996, The Journal of Biological Chemistry.
[93] H. Erdjument-Bromage,et al. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. , 1998, Genes & development.
[94] S. Teitelbaum,et al. Competition for a Unique Response Element Mediates Retinoic Acid Inhibition of Vitamin D3-stimulated Transcription* , 1996, The Journal of Biological Chemistry.
[95] P. Sambrook,et al. Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone , 1996, Current opinion in rheumatology.
[96] M. Haussler,et al. Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. , 1988, Endocrinology.
[97] P. N. MacDonald,et al. The N-terminal domain of transcription factor IIB is required for direct interaction with the vitamin D receptor and participates in vitamin D-mediated transcription. , 1997, Molecular endocrinology.
[98] C. Carlberg,et al. The high affinity ligand binding conformation of the nuclear 1,25-dihydroxyvitamin D3 receptor is functionally linked to the transactivation domain 2 (AF-2). , 1996, Nucleic acids research.
[99] B. O’Malley,et al. Functional domains of the human vitamin D3 receptor regulate osteocalcin gene expression. , 1989, Molecular endocrinology.
[100] M. Haussler,et al. Novel nuclear localization signal between the two DNA‐binding zinc fingers in the human vitamin D receptor , 1998, Journal of cellular biochemistry.
[101] D. Sherman,et al. The Vitamin D Receptor Interacts with General Transcription Factor IIB (*) , 1995, The Journal of Biological Chemistry.
[102] L. Freedman,et al. DNA sequences that act as high affinity targets for the vitamin D3 receptor in the absence of the retinoid X receptor. , 1994, Molecular endocrinology.
[103] I. Wang,et al. Interaction between the Retinoid X Receptor and Transcription Factor IIB Is Ligand-dependent in Vivo * , 1998, The Journal of Biological Chemistry.
[104] S. Krane,et al. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. , 1986, Cellular immunology.
[105] J. Shine,et al. ApaI dimorphism at the human vitamin D receptor gene locus. , 1989, Nucleic acids research.
[106] R. Kageyama,et al. Helix-loop-helix-type transcription factor (HES-1) is expressed in osteoblastic cells, suppressed by 1,25(OH)2 vitamin D3, and modulates 1,25(OH)2 vitamin D3 enhancement of osteopontin gene expression. , 1997, Bone.
[107] M. Waugh,et al. Decreased accessory cell function and costimulatory activity by 1,25-dihydroxyvitamin D3-treated monocytes. , 1992, Arthritis and rheumatism.
[108] H. DeLuca,et al. Cloning and origin of the two forms of chicken vitamin D receptor. , 1997, Archives of Biochemistry and Biophysics.
[109] P. Andrew,et al. 1α,25-Dihydroxyvitamin D3 and a Variety of its Natural Metabolites Transcriptionally Repress Nuclear-Factor-κB-Mediated Interleukin-8 Gene Expression , 1997 .
[110] E. Wagner,et al. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. , 1995, Cancer research.
[111] C. Mathieu,et al. Prevention of type I diabetes by late intervention with nonhypercalcemic analogues of vitamin D3 in combination with cyclosporin A. , 1996, Transplantation proceedings.
[112] F. Glorieux,et al. The 25‐Hydroxyvitamin D 1‐Alpha‐Hydroxylase Gene Maps to the Pseudovitamin D‐Deficiency Rickets (PDDR) Disease Locus , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[113] A. Norman,et al. Differential Interaction of 1α,25-Dihydroxyvitamin D3 Analogues and Their 20-epi Homologues with the Vitamin D Receptor* , 1997, The Journal of Biological Chemistry.
[114] L. Freedman,et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. , 1996, Genes & development.
[115] J. Reichrath,et al. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. , 1997, Journal of the American Academy of Dermatology.
[116] M. Garabedian,et al. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.
[117] P. Chambon,et al. Stimulation of RARα Activation Function AF-1 through Binding to the General Transcription Factor TFIIH and Phosphorylation by CDK7 , 1997, Cell.
[118] S. Krane,et al. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. , 1983, The Journal of clinical endocrinology and metabolism.
[119] J. Pike,et al. Hormone-dependent phosphorylation of the 1,25-dihydroxyvitamin D3 receptor in mouse fibroblasts. , 1985, Biochemical and biophysical research communications.
[120] H. DeLuca,et al. Immunocytology with microwave-fixed fibroblasts shows 1 alpha,25- dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors , 1990, The Journal of cell biology.
[121] H. Koeffler,et al. Structure-Function Studies on Analogues of 1α,25-Dihydroxyvitamin D3: Differential Effects on Leukemic Cell Growth, Differentiation, and Intestinal Calcium Absorption , 1990 .
[122] M. Becker‐André,et al. Interaction between retinoic acid and vitamin D signaling pathways. , 1993, The Journal of biological chemistry.
[123] H. DeLuca,et al. Vitamin D-dependency rickets type II: truncated vitamin D receptor in three kindreds , 1993, Molecular and Cellular Endocrinology.
[124] S. de Vos,et al. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. , 1995, Cancer research.
[125] M. Galligan,et al. The C-terminal region of the vitamin D receptor is essential to form a complex with a receptor auxiliary factor required for high affinity binding to the vitamin D-responsive element. , 1994, Molecular endocrinology.
[126] K. Kristjánsson,et al. Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. , 1993, The Journal of clinical investigation.
[127] Anthony W. Norman,et al. Vitamin D : chemistry, biology and clinical applications of the steroid hormone : proceedings of the Tenth Workshop on Vitamin D, Strasbourg, France, May 24-29, 1997 , 1997 .
[128] M. Galligan,et al. Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. , 1996, Molecular endocrinology.
[129] M. Haussler,et al. Inhibition of ligand induced promoter occupancy in vivo by a dominant negative RXR , 1996, Genes to cells : devoted to molecular & cellular mechanisms.
[130] G. Reddy,et al. 1,25-Dihydroxy-24-OXO-16ene-vitamin D3, a renal metabolite of the vitamin D analog 1,25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. , 1994, Endocrinology.
[131] R. Bouillon,et al. Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. , 1997, The Journal of clinical investigation.
[132] L. Freedman,et al. Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation. , 1999, The Journal of nutrition.
[133] G. Martin,et al. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.
[134] Bernhard Lüscher,et al. Characterization of the Transcriptional Regulator YY1 , 1997, The Journal of Biological Chemistry.
[135] J. Pike,et al. Vitamin D receptor interaction with specific DNA. Association as a 1,25-dihydroxyvitamin D3-modulated heterodimer. , 1991, The Journal of biological chemistry.
[136] L. Freedman. Anatomy of the steroid receptor zinc finger region. , 1992, Endocrine reviews.
[137] M. Campbell,et al. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. , 1997, Journal of molecular endocrinology.
[138] H. DeLuca,et al. Vitamin D and Multiple Sclerosis , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[139] H. Sakagami,et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[140] K. Kragballe. Calcipotriol: a new drug for topical psoriasis treatment. , 1995, Pharmacology & toxicology.
[141] L. Binderup,et al. Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. , 1997, Biochemical pharmacology.
[142] M. Karin,et al. Altering the specificity of signal transduction cascades: positive regulation of c‐Jun transcriptional activity by protein kinase A. , 1994, The EMBO journal.
[143] D. Bikle,et al. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells. , 1996, Cancer research.
[144] M. Lazar. Thyroid hormone receptors: multiple forms, multiple possibilities. , 1993, Endocrine reviews.
[145] H. DeLuca,et al. 1,25-Dihydroxyvitamin D in biological fluids: a simplified and sensitive assay. , 1976, Science.
[146] B. Frenkel,et al. YY1 regulates vitamin D receptor/retinoid X receptor mediated transactivation of the vitamin D responsive osteocalcin gene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[147] M. Haussler,et al. The 1,25-dihydroxy-vitamin D3 receptor is phosphorylated in response to 1,25-dihydroxy-vitamin D3 and 22-oxacalcitriol in rat osteoblasts, and by casein kinase II, in vitro. , 1993, Biochemistry.
[148] M. Montminy,et al. Role of CBP/P300 in nuclear receptor signalling , 1996, Nature.
[149] B. Howard,et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A , 1996, Nature.
[150] P. Price,et al. Ligand-dependent regulation of the 1,25-dihydroxyvitamin D3 receptor in rat osteosarcoma cells. , 1987, The Journal of biological chemistry.
[151] Hueng-Sik Choi,et al. Steroid Receptor Coactivator-1 Interacts with the p50 Subunit and Coactivates Nuclear Factor κB-mediated Transactivations* , 1998, The Journal of Biological Chemistry.
[152] P. Brachet,et al. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. , 1997, Brain research. Molecular brain research.
[153] R. Cook,et al. 1,25-dihydroxyvitamin D3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation. , 1994, Biochemistry.
[154] J. Eisman,et al. Prediction of bone density from vitamin D receptor alleles , 1994, Nature.
[155] D. Heber,et al. and Inducers of Differentiation of Human Breast Cancer Cell Lines , 1995 .
[156] A. Turner,et al. Safety and efficacy of oral calcitriol (1, 25 ‐dihydroxyvitamin D3) for the treatment of psoriasis , 1996, The British journal of dermatology.
[157] D. Feldman,et al. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. , 1993, Endocrinology.
[158] K. Meerovitch,et al. Identification and Characterization of 1,25-Dihydroxyvitamin D3-responsive Repressor Sequences in the Rat Parathyroid Hormone-related Peptide Gene* , 1996, The Journal of Biological Chemistry.
[159] L. Freedman,et al. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor , 1995, Molecular and cellular biology.
[160] Ames,et al. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. , 1997, The New England journal of medicine.
[161] P. Chambon,et al. The dimerization interfaces formed between the DNA binding domains of RXR, RAR and TR determine the binding specificity and polarity of the full‐length receptors to direct repeats. , 1994, The EMBO journal.
[162] H. DeLuca,et al. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[163] Hui Li,et al. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[164] S. Wölfl,et al. L7 protein is a coregulator of vitamin D receptor‐retinoid X receptor‐mediated transactivation , 1998, Journal of cellular biochemistry.
[165] M. Parker,et al. Interaction of proteins with transcriptionally active estrogen receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[166] F. Révillion,et al. Vitamin‐D3 derivatives and breast‐tumor cell growth: Effect on intracellular calcium and apoptosis , 1995, International journal of cancer.
[167] A. Wolffe,et al. Histone acetylation: chromatin in action. , 1997, Trends in biochemical sciences.
[168] K. Umesono,et al. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors , 1991, Cell.
[169] A. Norman,et al. Distinct Conformational Changes Induced by 20-epi Analogues of 1,25-Dihydroxyvitamin D Are Associated with Enhanced Activation of the Vitamin D Receptor (*) , 1995, The Journal of Biological Chemistry.
[170] G. Karsenty,et al. Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.
[171] S. Teitelbaum,et al. Cloning of the promoter for the avian integrin beta 3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3. , 1993, The Journal of biological chemistry.
[172] D. Feldman,et al. Cyclic adenosine 3',5'-monophosphate up-regulates 1,25-dihydroxyvitamin D3 receptor gene expression and enhances hormone action. , 1992, Molecular endocrinology.
[173] T. Baudino,et al. Isolation and Characterization of a Novel Coactivator Protein, NCoA-62, Involved in Vitamin D-mediated Transcription* , 1998, The Journal of Biological Chemistry.
[174] J. Levy,et al. Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8). , 1992, Endocrinology.
[175] J. Y. Chen,et al. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. , 1992, Cell.
[176] E. Appella,et al. H‐2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes. , 1992, The EMBO journal.
[177] M. Haussler,et al. New insight into the structure and functions of the vitamin D receptor. , 1994, Seminars in nephrology.
[178] J. Williams,et al. Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. , 1995, Anti-cancer drugs.
[179] R. Roeder,et al. The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[180] J. Eisman,et al. Regulation of the 1,25-dihydroxyvitamin D3 receptor by 1,25-dihydroxyvitamin D3 in intact human cancer cells. , 1985, Endocrinology.
[181] M. Haussler,et al. Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. , 1987, Science.
[182] J. Shine,et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[183] D. Bikle,et al. Cloning of the Human Phospholipase C-γ1 Promoter and Identification of a DR6-type Vitamin D-responsive Element* , 1997, The Journal of Biological Chemistry.
[184] I. Reid,et al. Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo. , 1997, Endocrinology.
[185] H. DeLuca,et al. The Sp1 transcription factor gene (SP1) and the 1,25-dihydroxyvitamin D3 receptor gene (VDR) are colocalized on human chromosome arm 12q and rat chromosome 7. , 1991, Genomics.
[186] B. O’Malley,et al. An ochre mutation in the vitamin D receptor gene causes hereditary 1,25-dihydroxyvitamin D3-resistant rickets in three families. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[187] J. Eisman,et al. 1,25-Dihydroxyvitamin D3 and the Regulation of Human Cancer Cell Replication 1 , 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[188] H. DeLuca,et al. 1 alpha, 25-Dihydroxyvitamin D3 and 19-nor-1 alpha, 25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. , 1993, Biochimica et biophysica acta.
[189] T. Stamey,et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.
[190] R. Schwartz. Sunlight—Can it prevent as well as cause cancer? , 1996 .
[191] J. Gustafsson,et al. A regulatory role for RIP140 in nuclear receptor activation. , 1998, Molecular endocrinology.
[192] C. Bunce,et al. Treatment of HL60 cells with various combinations of retinoids and 1 alpha,25 dihydroxyvitamin D3 results in differentiation towards neutrophils or monocytes or a failure to differentiate and apoptosis. , 1995, Leukemia.
[193] R. Mason,et al. Human melanocytes as a target tissue for hormones: in vitro studies with 1 alpha-25, dihydroxyvitamin D3, alpha-melanocyte stimulating hormone, and beta-estradiol. , 1988, The Journal of investigative dermatology.
[194] Allan Bradley,et al. Increased bone formation in osteocalcin-deficient mice , 1996, Nature.
[195] H. DeLuca,et al. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[196] L. M. Atkins,et al. Mapping the domains of the interaction of the vitamin D receptor and steroid receptor coactivator-1. , 1998, Molecular endocrinology.
[197] B. O’Malley,et al. Mouse retinoid X receptor contains a separable ligand-binding and transactivation domain in its E region , 1995, Molecular and cellular biology.
[198] P. Brachet,et al. 1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. , 1994, Brain research. Molecular brain research.
[199] A. Aranda,et al. Vitamin D interferes with transactivation of the growth hormone gene by thyroid hormone and retinoic acid , 1996, Molecular and cellular biology.
[200] A. Norman,et al. Factors affecting the distribution and stability of unoccupied 1,25-dihydroxyvitamin D3 receptors. , 1981, Journal of receptor research.
[201] H. DeLuca,et al. Phosphorylation is involved in transcriptional activation by the 1,25-dihydroxyvitamin D3 receptor. , 1993, Biochimica et biophysica acta.
[202] R. Mason,et al. Human Melanocytes as a Target Tissue for Hormones: In Vitro Studies with 1α-25, dihydroxyvitamin D3, α-melanocyte Stimulating Hormone, and Beta-estradiol , 1988 .
[203] H. DeLuca,et al. Stabilization of the vitamin D receptor in rat osteosarcoma cells through the action of 1,25-dihydroxyvitamin D3. , 1993, Molecular endocrinology.
[204] R. Mehta,et al. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. , 1997, Journal of the National Cancer Institute.
[205] K. Umesono,et al. Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene , 1990, Cell.
[206] D. Ledbetter,et al. Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13–14 , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[207] R. Evans,et al. A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.
[208] L. Rorke,et al. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[209] Raoul C. M. Hennekam,et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP , 1995, Nature.
[210] Christopher K. Glass,et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.
[211] M. Haussler,et al. New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. , 1995, Bone.
[212] K. Ozono,et al. Functional Assessment of Two Vitamin D-responsive Elements in the Rat 25-Hydroxyvitamin D3 24-Hydroxylase Gene* , 1996, The Journal of Biological Chemistry.
[213] R. Bouillon,et al. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 α, 25-(OH)2D3 , 1995, Journal of Neuroimmunology.
[214] C. Hahn,et al. Transcriptional Synergism between Vitamin D-responsive Elements in the Rat 25-Hydroxyvitamin D3 24-Hydroxylase (CYP24) Promoter* , 1996, The Journal of Biological Chemistry.
[215] P. Kerkhof,et al. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long‐term treatment with the vitamin D3 analogue MC903: modulations and interrelations , 1991 .
[216] J. Direnzo,et al. p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[217] F. Dilworth,et al. Increased biological activity of 20-epi-1,25-dihydroxyvitamin D3 is due to reduced catabolism and altered protein binding. , 1994, Biochemical pharmacology.
[218] G. Rodan,et al. The Missing Bone , 1997, Cell.
[219] E. Slatopolsky,et al. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. , 1995, Endocrinology.
[220] R. Wernyj,et al. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. , 1996, The Biochemical journal.
[221] R. Bouillon,et al. Enhancement of antiproliferative activity of 1α,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[222] H. DeLuca,et al. Id gene expression and its suppression by 1,25-dihydroxyvitamin D3 in rat osteoblastic osteosarcoma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[223] J. Barsony,et al. Subcellular Distribution of Normal and Mutant Vitamin D Receptors in Living Cells , 1997, The Journal of Biological Chemistry.
[224] J. Welsh. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. , 1994, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[225] I. Yokota,et al. A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single-strand conformation polymorphism analysis for heterozygous carrier detection. , 1991, American journal of human genetics.
[226] L. Freedman,et al. Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers , 1994, Molecular and cellular biology.
[227] M. Holick,et al. Efficacy and safety of topical calcitriol (1,25‐dihydroxyvitamin D3) for the treatment of psoriasis , 1996, The British journal of dermatology.
[228] P. Malloy,et al. Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. , 1994, The Journal of clinical endocrinology and metabolism.
[229] M. Cippitelli,et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. , 1998, The Journal of clinical investigation.
[230] H. DeLuca,et al. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. , 1998, The Journal of nutrition.
[231] Y. Masuhiro,et al. Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. , 1995, Biochemistry.
[232] M. Haussler,et al. Mutations in the 1,25-Dihydroxyvitamin D3 Receptor Identifying C-terminal Amino Acids Required for Transcriptional Activation That Are Functionally Dissociated from Hormone Binding, Heterodimeric DNA Binding, and Interaction with Basal Transcription Factor IIB, in Vitro * , 1997, The Journal of Biological Chemistry.
[233] E. Rosen,et al. Dimerization interfaces of thyroid hormone, retinoic acid, vitamin D, and retinoid X receptors. , 1993, The Journal of biological chemistry.
[234] H. Jüppner,et al. Cloning and characterization of the vitamin D receptor from Xenopus laevis. , 1997, Endocrinology.
[235] Y. Miyamoto,et al. Regulation of vitamin D-responsive gene expression by fluorinated analogs of calcitriol in rat osteoblastic ROB-C26 cells. , 1995, Journal of biochemistry.
[236] P. Harnden,et al. Immunocytochemical detection of a reduction in 1,25 dihyroxyvitamin D3 receptor expression in uraemic parathyroid tissue. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[237] R. Evans,et al. The RXR heterodimers and orphan receptors , 1995, Cell.
[238] K. Kragballe,et al. The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. , 1996, The journal of investigative dermatology. Symposium proceedings.
[239] P. Chambon,et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. , 1995, Nature.
[240] J. Eisman,et al. 1α,25‐Dihydroxyvitamin D3 receptor as a mediator of transrepression of retinoid signaling , 1997 .
[241] D. Feldman,et al. Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies. , 1980, The Journal of clinical endocrinology and metabolism.
[242] Mary E. McGrath,et al. A structural role for hormone in the thyroid hormone receptor , 1995, Nature.
[243] B. Spiegelman,et al. Pleiotropic effects of a null mutation in the c-fos proto-oncogene , 1992, Cell.
[244] R. Bouillon,et al. Vitamin D analogs with low affinity for the vitamin D binding protein: Enhanced in vitro and decreased in vivo activity , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[245] C. Glass,et al. Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding , 1994, Nature.
[246] J. Weissenbach,et al. Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians. , 1996, American journal of human genetics.
[247] P. Chambon,et al. Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells. , 1997, Genes & development.
[248] J. Pike,et al. Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[249] J M Lemire,et al. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. , 1991, The Journal of clinical investigation.
[250] M. Galligan,et al. Phosphorylation of the human vitamin D receptor by protein kinase C. Biochemical and functional evaluation of the serine 51 recognition site. , 1993, The Journal of biological chemistry.
[251] J. Adams,et al. 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. , 1984, The Journal of clinical investigation.
[252] B. Komm,et al. Molecular biology of the vitamin D hormone. , 1988, Recent progress in hormone research.
[253] C. Carlberg,et al. Identification of a vitamin D receptor homodimer-type response element in the rat calcitriol 24-hydroxylase gene promoter. , 1994, Biochemical and biophysical research communications.
[254] J. Geysen,et al. Proliferation and differentiation of cultured human keratinocytes is modulated by 1,25(OH)2D3 and synthetic vitamin D3 analogues in a cell density-, calcium- and serum-dependent manner. , 1997, Pharmacology & toxicology.
[255] H. Koeffler,et al. Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. , 1991, Blood.
[256] J. Eisman,et al. Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancers. , 1986, Cancer research.
[257] C. Mathieu,et al. Prevention of diabetes recurrence after syngeneic islet transplantation in NOD mice by analogues of 1,25(OH)2D3 in combination with cyclosporin A: mechanism of action involves an immune shift from Th1 to Th2. , 1998, Transplantation proceedings.
[258] C. Allis,et al. Steroid receptor coactivator-1 is a histone acetyltransferase , 1997, Nature.
[259] R. Horst,et al. Intracellular location of unoccupied 1,25-dihydroxyvitamin D receptors: a nuclear-cytoplasmic equilibrium. , 1986, Archives of biochemistry and biophysics.
[260] H. Yamamoto,et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. , 1997, Molecular endocrinology.
[261] S. Mundlos,et al. Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development , 1997, Cell.
[262] R. Evans,et al. Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.
[263] M. Favus,et al. Structure-function relationship of human parathyroid hormone in the regulation of vitamin D receptor expression in osteoblast-like cells (ROS 17/2.8). , 1995, Endocrinology.
[264] B. O’Malley,et al. Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.
[265] C. Glass. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. , 1994, Endocrine reviews.
[266] J. Eisman,et al. Whole-cell uptake and nuclear localization of 1,25-dihydroxycholecalciferol by breast cancer cells (T47 D) in culture. , 1981, The Biochemical journal.
[267] L. Freedman,et al. Retinoid X receptor:vitamin D3 receptor heterodimers promote stable preinitiation complex formation and direct 1,25-dihydroxyvitamin D3-dependent cell-free transcription , 1997, Molecular and cellular biology.
[268] J. Pike,et al. Transcriptional activation and dimerization functions in the human vitamin D receptor. , 1996, Molecular endocrinology.
[269] H. Samuels,et al. Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. , 1990, Molecular endocrinology.
[270] T. Martin,et al. Expression of parathyroid hormone‐related protein in cells of osteoblast lineage , 1996, Journal of cellular physiology.
[271] R. St-Arnaud,et al. Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. , 1997, Molecular endocrinology.
[272] C. Glass,et al. Nuclear receptor coactivators. , 2000, Advances in pharmacology.
[273] C. Glass,et al. Multiple cell type-specific proteins differentially regulate target sequence recognition by the α retinoic acid receptor , 1990, Cell.
[274] S. de Vos,et al. 1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia. , 1994, Leukemia research.
[275] L. Freedman,et al. Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene. , 1996, The Biochemical journal.
[276] P. Chambon,et al. Purification, functional characterization, and crystallization of the ligand binding domain of the retinoid X receptor. , 1995, Protein expression and purification.